GSK/Xenoport’s Sustained-Release Restless Legs Drug Shows Efficacy
This article was originally published in Pharmaceutical Approvals Monthly
Data from a pivotal study presented at the American Academy of Neurology meeting April 17, evaluating GlaxoSmithKline/Xenoport's sustained-release restless legs syndrome drug XP13512, added further evidence to support its safety and efficacy
You may also be interested in...
UCB could bring the first competitor to GlaxoSmithKline's Requip (ropinirole) for restless leg syndrome to market later this year after submitting an sNDA for Neupro (rotigotine) for RLS
The ADC specialist could have a fourth cancer drug on the market this year and is preparing for its first commercial launch in Europe.
The virtual J.P. Morgan Healthcare meeting was missing the usual energy but still had substance.